Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Media Centre
Overview
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Heading &
Sub-heading can be edited through HQI
Home
>
For Investors
>
ASX Announcements
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
ASX Announcements
Filter by Year:
2023
2022
2021
2020
2019
2018
18-Oct-2018
Kazia raises $3.4m to progress R&D programs
17-Oct-2018
Suspension from Official Quotation
15-Oct-2018
Trading Halt
11-Oct-2018
Presentation to Finance News Network Investor Event
10-Oct-2018
Cantrixil Part A completion
8-Oct-2018
Kazia Notice of Meeting
8-Oct-2018
Kazia Annual Report to shareholders, Appx 4G, Corporate Governance Statement
3-Oct-2018
Kazia change in interest of substantial shareholder
3-Oct-2018
Kazia collaborates with St Jude Children's Research Hospital
14-Sep-2018
Kazia attains Milestone 1 under Glioblast Purchase Agreement
Previous
1
2
3
4
5
6
Next